EUROCAT; an update on its functions and activities

Tucker FD\textsuperscript{a}, Morris JK\textsuperscript{b}, on behalf of the JRC Management Committee (Neville A Garne\textsuperscript{e}, Kinsner-Ovaskainen\textsuperscript{A}, Lanzoni\textsuperscript{M}, Loane\textsuperscript{MA}, Martin\textsuperscript{S}, Nicholl\textsuperscript{C}, Rankin\textsuperscript{J}, Rissmann\textsuperscript{Ak},)

\textsuperscript{a} Congenital Anomaly Register & Information Service for Wales (CARIS) Public Health Wales, Swansea, UK
\textsuperscript{b} Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK
\textsuperscript{c} IMER Registry (Emilia Romagna Registry of Birth Defects), University of Ferrara and Azienda Ospedaliero Universitaria di Ferrara, Italy
\textsuperscript{d} Paediatric Department, Hospital Lillebaelt, Kolding, Denmark
\textsuperscript{e} DG Joint Research Centre, Directorate F – Health Consumers and Reference Materials, Ispra, Italy
\textsuperscript{f} DG Joint Research Centre, Directorate F – Health Consumers and Reference Materials, Ispra, Italy
\textsuperscript{g} Institute of Nursing and Health Research, Ulster University, Newtownabbey, UK
\textsuperscript{h} DG Joint Research Centre, Directorate F – Health Consumers and Reference Materials, Ispra, Italy
\textsuperscript{i} Institute of Health and Society, Newcastle University, Newcastle, UK
\textsuperscript{j} Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

Corresponding Author: David Tucker – david.tucker2@wales.nhs.uk, 044 1792 285241 or 07845231969

EUROCAT, founded in 1979 as the European Concerted Action on Congenital Anomalies and Twins, is a high quality network of population based congenital anomaly registries across Europe for the monitoring, surveillance and research of congenital anomalies\textsuperscript{1}. Since its conception the European Commission (EC) has funded the EUROCAT Central Registry.

The EUROCAT Central Registry was based in Brussels from 1979 to 1999 and then moved to the UK. From 2000 to 2014 it was accommodated at the University of Ulster, led superbly by Professor Helen Dolk. In January 2015 the Central Registry transferred to the European Commission’s Joint Research Centre (DG JRC) in Ispra, Italy. EUROCAT is now an integral part of the European Platform on Rare Diseases Registration being developed at the JRC\textsuperscript{2} in close collaboration with the EC’s Directorate for Health and Food safety (DG SANTE).

Over the last two decades EUROCAT has grown, developed and matured in many directions to be the successful network that is recognised around the world today. (Other research groups now apply our methodology and use our publications as reference). Greater standardisation of definitions, diagnoses and terminology were achieved, principally by the development of the EUROCAT guides (currently version 1.4)\textsuperscript{3}, the EUROCAT Central Database and the EUROCAT Data Management Program (ECD and EDMP)\textsuperscript{4} which constrained registers to adopt common practices in data reporting. The EUROCAT Coding and Classification Committee from 2003 onwards also played its role, by defining cases, developing and disseminating rules around classification and coding and providing support and training in applying these rules.

Currently, the EUROCAT Central Registry holds details on approximately 750,000 cases of congenital anomalies collected over the years by 51 registries, contributing either anonymous individual case specific data (full members) or aggregate prevalence data in tables (associate members), from 23 countries covering almost 30% of European births (1.7 million) per year.

The great value of EUROCAT is that the data are collected, coded and stored by local registries in a standardised way. This inherent homogeneity in the data across Europe\textsuperscript{5} overcomes the weaknesses of many studies which attempt to derive information from heterogeneous datasets.
One key function of EUROCAT is to publish statistics on outcomes and prevalence rates for a wide range of major congenital anomalies annually. The data covers all pregnancy outcomes (including terminations) from 20 weeks gestation. Much of this information is freely available on the EUROCAT website. Having good quality baseline background data is vital when considering possible environmental impacts. A recent publication highlighted the differences in the diagnosis of microcephaly across Europe, a matter of importance when interpreting the prevalence of microcephaly across South America with the emergence of Zika virus. The value of robust baseline data has also been demonstrated by work undertaken in Italy, investigating environmental exposures.

EDMP has a built-in module for calculating trends and clusters, designed as an “early response” system. This can be used by individual registers to review their own data or by the Central Registry combining data. It is interesting to see that what can often appear to be a local or national trend to an individual register or group of registers within one country can in fact be part of something wider and larger across the whole of Europe. Trends may increase because of better diagnosis (improvements in antenatal ultrasound scanning for example) or because of environmental factors that are not well understood. For instance there is marked variation in the prevalence of gastroschisis in some northern European countries compared to the Mediterranean region. On the other hand the increasing use of ultrasound scans pre and postnatally has made it more difficult to determine and harmonise the exact limit between normal and abnormal findings in fetuses and newborn babies.

However, perhaps the greatest value of combining data can be seen for rare diseases. No individual registry will ever have enough cases to accurately determine prevalence for rare and very rare conditions. By combining data this can be achieved. Over recent years, EUROCAT papers have been published on Holt-Oram syndrome, Meckle-Gruber syndrome, Ocular-Auricular-Vertebral syndrome and Fraser syndrome. The value of combining data can be seen even in common conditions such as trisomy 21, where factors such as twinning require Europe-wide data in order to be explored effectively. EUROCAT representatives are also involved with some of the recently established European Reference Networks (ERNS) for rare diseases.

Another area of interest is the impact of health service policies and practice. Improvements in antenatal detections of anomalies and increasing survival for live born infants seen with cardiac anomalies demonstrate this. Other work includes the development of indicators to summarise the public health impact of congenital anomalies, including mortality. Survival to 1 week and 1 year varies enormously between countries mainly because of different legislation regarding termination. Death at 1 week is much higher in those countries where terminations are not legal (Malta and Ireland) compared to other countries.

The lack of fortification of foodstuffs with folic acid in European countries has been a matter of deep regret to EUROCAT. Whilst the United States, Canada and other places have been able to demonstrate a significant fall in the rates of neural tube defects due to fortification, EUROCAT consistently reports that neural defects rates across Europe remain stubbornly stable. Sadly this demonstrates usefulness in highlighting a failure of Public Health action in the European member states.

EUROCAT continues to develop methods to improve the surveillance of congenital anomalies. One example is the development of a coding algorithm, which has been implemented in EDMP to allow
for classification of multiple congenital anomalies where there is no unifying diagnosis of a syndrome or chromosomal anomaly for separate surveillance. Patterns of occurrence are looked for, which may suggest possible pathways for teratogens, or other aetiological causation.\textsuperscript{31}

Pharmacovigilance has been an area of study of increasing importance over the last 10 years.\textsuperscript{32, 33} EUROCAT has demonstrated the value of such work, particularly through the EUROMediCAT project\textsuperscript{34} in which medications taken during the first trimester of pregnancy, for certain long-term or chronic diseases have been assessed. The medications studied include anti-epileptics, SSRIs, anti-asthmatics, and diabetic medicines. The EUROMediCAT project involved a data-linkage approach between registers and national prescription databases.

Recently a new data-linkage project has been launched – EUROlinkCAT\textsuperscript{35} funded by the Horizon 2020 project. By linking data between registers and other national databases, it is hoped that a far more detailed and extensive picture can be described on the long-term consequence for infants born with major congenital anomalies; consequences in terms of survival, morbidity, health service usage and demands, and educational achievement.

These linkage projects highlight a widespread change in registration practice in recent years, with less reliance upon paper reports and linkage to health databases and systems becoming routine at the local level.

Collaborative studies are often developed by thematic Working Groups that are constituted whenever new research needs arise. Two recently established groups are Genetics, and Health Inequalities. In this way EUROCAT remains relevant and flexible to adapt to changes in the clinical world.

EUROCAT is an invaluable resource. With so many opportunities for further studies, and for pushing forward the scientific understanding of congenital anomalies, a bright future for EUROCAT beckons. We are confident that being part of the European Platform on Rare Disease Registration will give the stability and support to build upon EUROCAT’s past successes and to achieve even greater things in the years ahead.

**Compliance with Ethic guidelines.**

The authors have are no conflicts of interest.

This article does not contain any studies with human or animal subjects performed by the any of the authors.

**Bibliography**


